Friedman Eric J 4/A

What Happened

• Eric J. Friedman, a director of Integrated BioPharma, was granted 50,000 derivative securities (stock options) on 2026-06-24. The filing reports a $0.00 acquisition price and $0 total in the Form 4 entry, reflecting an award/grant (not a cash purchase or exercised options).

Key Details

• Transaction date: 2026-06-24; Form 4 filed as an amendment on 2026-06-25 to correct the reported quantity.
• Grant size: 50,000 stock options (derivative securities); filing shows $0.00 per share and $0 total for the reported transaction.
• Shares/options owned after transaction: 50,000 derivative securities beneficially owned (amendment corrected this from an earlier incorrect "50").
• Footnote: Options vest in four equal installments of 12,500 each on Sept 30, 2026; Dec 31, 2026; Mar 31, 2027; and Jun 30, 2027.
• Timeliness/Amendment: This is an amended filing correcting Box 9 (number of derivative securities following the transaction). The amendment was filed the day after the reported transaction.

Context

• This was a grant/award of options (A), not an exercise or sale. The filing’s $0.00 entry reflects the award reporting on Form 4; it does not mean the options were exercised for no cost. Vesting schedule means Friedman must wait for future dates before options become exercisable. Awards are common for compensation and do not by themselves indicate immediate buying/selling intent.